3.64 USD
▲+0.50+15.92%
盘后 3.66 +0.55%
2026-09-15
市值
$427.71M
市盈率
—
EPS
-0.47
股息率
—
52 周区间
0.92 – 8.57
成交量
1.96M
Beta
1.17
目标价
—
52W 低 0.9252W 高 8.57
价格走势
公司简介
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and ...